Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use

By LabMedica International staff writers
Posted on 23 Oct 2026

Vaginitis affects most women at least once in their lifetime and can cause painful, disruptive symptoms. More...

Common causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, reflecting microbiome imbalance or infection. Diagnosing these conditions can be challenging when traditional methods are subjective or lack sensitivity. To support more reliable assessment, a newly cleared point-of-care molecular test provides multiple vaginitis results from a single vaginal swab in about 20 minutes.

bioMérieux’s BioFire Spotfire Vaginitis (VG) Panel has received both 510(k) clearance and a CLIA waiver from the U.S. Food and Drug Administration (FDA). The automated multiplex PCR assay runs on the BioFire Spotfire Vaginitis System, bringing molecular vaginitis testing to the point of care. With the CLIA waiver, non-laboratory professionals can perform the test in point-of-care settings.

The panel reports eight results from a single vaginal swab, covering bacterial vaginosis, yeast pathogens, and the parasite Trichomonas vaginalis. For bacterial vaginosis, the result is informed by an algorithm that assesses the relative abundance of multiple bacteria and provides a binary result. The yeast component includes Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, and Candida dubliniensis.

The assay can be run with self-collected or clinician-collected vaginal swabs, offering options for different patients and healthcare settings. Only about half of women diagnosed with vaginitis by non-molecular testing receive appropriate treatment. The test is intended to provide rapid results during a typical patient visit, supporting treatment decisions during the same encounter.

The BioFire SpotfireVaginitis (VG) Panel expands bioMérieux’s point-of-care portfolio, which includes panels for respiratory and sore throat infections on the same system. The modular instrument has a small footprint and is designed for healthcare settings including family care practices, urgent care sites, and obstetrician/gynecologist offices. The panel is planned to be commercially available in the United States at the beginning of 2027, followed by an extended worldwide rollout.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.